Comparative Pharmacology
Head-to-head clinical analysis: FLUTICASONE PROPIONATE versus SYMBICORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUTICASONE PROPIONATE versus SYMBICORT.
FLUTICASONE PROPIONATE vs SYMBICORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucocorticoid receptor agonist; binds to cytosolic glucocorticoid receptors, leading to inhibition of inflammatory mediators (e.g., cytokines, prostaglandins, leukotrienes) and suppression of immune cell activity.
Symbicort is a combination product containing budesonide, a corticosteroid, and formoterol fumarate dihydrate, a long-acting beta2-adrenergic agonist (LABA). Budesonide reduces inflammation by inhibiting inflammatory mediators and suppressing airway hyperresponsiveness. Formoterol stimulates beta2-adrenergic receptors in bronchial smooth muscle, leading to bronchodilation via increased cyclic AMP. The combination provides anti-inflammatory and bronchodilatory effects.
Inhalation: 88-440 mcg twice daily for asthma (DPI: 100-500 mcg twice daily; HFA: 44-220 mcg twice daily). Intranasal: 2 sprays (50 mcg/spray) per nostril once daily (total 200 mcg/day). Topical: Apply thin layer to affected area 1-2 times daily.
1-2 inhalations (80/4.5 mcg or 160/4.5 mcg) twice daily; maximum 2 inhalations twice daily of 160/4.5 mcg.
None Documented
None Documented
Clinical Note
moderateFluticasone propionate + Gatifloxacin
"The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Gatifloxacin."
Clinical Note
moderateFluticasone propionate + Rosoxacin
"The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Rosoxacin."
Clinical Note
moderateFluticasone propionate + Levofloxacin
"The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Levofloxacin."
Clinical Note
moderateTerminal elimination half-life is approximately 7.8 hours after intravenous administration; extends to 10-14 hours following intranasal or inhaled routes due to slow absorption from the lung/nasal mucosa.
Budesonide: 2–3 hours (terminal); Formoterol: 10 hours (terminal). Clinical context: Twice-daily dosing maintains bronchodilation.
Primarily hepatic metabolism via CYP3A4 to inactive metabolites; <5% excreted unchanged in urine; biliary/fecal elimination accounts for >90% of metabolites.
Budesonide: 60% renal (as metabolites), 40% fecal; Formoterol: 60% renal (as metabolites), 40% fecal.
Category A/B
Category C
Inhaled Corticosteroid
Inhaled Corticosteroid/Long-Acting Beta Agonist
Fluticasone propionate + Trovafloxacin
"The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Trovafloxacin."